BCM
ADCT icon

Burrage Capital Management’s ADC Therapeutics ADCT Stock Holding History

Burrage Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-124,875
Closed -$3.04M – 1
2021
Q2 		$3.04M Hold
124,875
– – 3.05% 14
2021
Q1 		$3.05M Sell
124,875
-975
-0.8% -$28.2K 2.47% 21
2020
Q4 		$4.03M Sell
125,850
-9,062
-7% -$297K 3.07% 15
2020
Q3 		$4.45M Hold
134,912
– – 3.51% 14
2020
Q2 		$6.32M Buy
+134,912
New +$5.12M 4.42% 8

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Burrage Capital Management's ADCT Position: Q3 2021 in Review

Burrage Capital Management sold out of ADC Therapeutics (ADCT) in Q3 2021, closing a stake of 124,875 shares — an estimated $3.04M sold.

Burrage Capital Management first reported a position in ADCT in Q2 2020 and held it in 5 quarters. The position peaked at $6.32M in Q2 2020. 53 funds tracked by Wall St. Rank hold ADCT as of Q3 2021.

  • Burrage Capital Management reported no remaining ADC Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Burrage Capital Management sold 124,875 ADC Therapeutics shares in Q3 2021, an estimated $3.04M.
  • Burrage Capital Management first reported a position in ADC Therapeutics in Q2 2020 and held it in 5 quarters.
  • Burrage Capital Management's ADC Therapeutics position peaked at $6.32M in Q2 2020.
  • 53 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2021.

Based on Burrage Capital Management's 13F filing for Q3 2021.